September 25, 2024 03:28 PM EDT
Pharma
FDA+

EMA to dis­cuss Pfiz­er's sick­le cell drug Oxbry­ta af­ter pa­tient deaths

Nicole DeFeudis

Editor

The Eu­ro­pean Med­i­cines Agency will meet on Thurs­day to dis­cuss Oxbry­ta — the sick­le cell treat­ment Pfiz­er in­her­it­ed in its $5.4 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

Flag­ship launch­es start­up to de­sign and make lipid nanopar­ti­cles for ge­net­ic med­i­cines

A Parkin­son's drug that Ab­b­Vie ac­quired from Cerev­el suc­ceeds in an­oth­er Phase 3

SIGA is 'deeply an­gered' by for­mer ex­ec's 'i­nac­cu­rate' com­ments about mpox an­tivi­ral

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times